Digital Trials Digest, our quarterly newsletter
In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.
When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.
For patients with rare, incurable, or life-threatening diseases, clinical trials can offer new hope. Cancer patients, specifically, are often highly motivated to participate in research, particularly when they have an advanced or treatment-resistant form of cancer. Find out how decentralized clinical trials reach patients in the comfort of their homes.
While there's broad agreement on the gap between white and non-white participation in clinical trial enrollment, the number of non-white patients enrolled in clinical trials for general population studies is still quite low. But why?
Digital instruments such as sensors and wearables are transforming the industry’s definition of accuracy in three measures: volume, practicality, and precision.
The rapid expansion of the clinical research market in the Asia-Pacific (APAC) region has opened up significant prospects for carrying out decentralized clinical trials there.
Unstructured data collection from image capture technology can be harnessed to improve the quality of patient-reported data and serve as the bedrock for the training of new algorithms that can help clinicians more accurately diagnose disease.
Enhancing Electronic Patient-Reported Outcomes with digital instruments streamlines and accelerates data collection, making clinical trials more accessible.
This study collected and compared stool ratings from caregivers (Group A), central raters (Group B), and pediatric gastroenterologists (Group C) to discover whether the level of stool consistency of a given photo is more prone to inter-rater variability. The study's results evidence inter-rater variability that is different across Bristol Stool Scale (BSS), which motivates research into standardized training or automated scoring, with a special emphasis on BSS.
Moving into 2022, decentralized models, propelled by breakthroughs in digital technology, will continue to reshape the industry, improving trial outcomes.